Introduction
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In June 2012, a previously unknown coronavirus was isolated from a patient who died from 62 acute pneumonia and renal failure in Saudi Arabia (1, 2) . Since then the virus, now known as 63 the Middle East respiratory syndrome coronavirus (MERS-CoV; (3)), was contracted by 64 hundreds of others in geographically distinct locations in the Middle East and evidence for 65 limited human-to-human transmission accumulated (4). Travel-related MERS-CoV infections 66 were reported from a variety of countries in Europe, Africa, Asia and the U.S.A., causing small 67 local infection clusters in several cases 68 (http://www.who.int/csr/disease/coronavirus_infections/en/). About 200 laboratory-confirmed 69 human MERS cases were registered during the first two years of this outbreak, but recently, for 70 reasons that are poorly understood thus far, this number has almost tripled within just two 71 months' time (April-May 2014; (5) ). This sharp increase in reported infections has enhanced 72 concerns that we might be confronted with a repeat of the 2003 severe acute respiratory 73 syndrome (SARS) episode, concerns aggravated by the fact that the animal reservoir for MERS- 74 CoV remains to be identified with certainty (6) (7) (8) (9) . Furthermore, at about 30%, the current 75 human case fatality rate is alarmingly high, even though many deaths were associated with 76 underlying medical conditions. MERS-CoV infection in humans can cause clinical symptoms 77 resembling SARS, such as high fever and acute pneumonia, although the two viruses were 78 reported to use different entry receptors, dipeptidyl peptidase 4 (DPP4; (10)) and angiotensin- 79 converting enzyme 2 (ACE2; (11)), respectively. Coronaviruses are currently divided across four genera (alpha-, beta-, gamma-, and 81 deltacoronaviruses; (12)). MERS-CoV was identified as a member of lineage C of the genus 82 Betacoronavirus (2), which also includes coronaviruses of bat (13, 14) and hedgehog origin (6). 83 Following the 2003 SARS epidemic, studies into the complex genome, proteome, and 84 replication cycle of coronaviruses were intensified. Coronaviruses are enveloped viruses with a 85 positive-sense RNA genome of unprecedented length (25 to 32 kb; (12, 15, 16) ). The crystal 86 structures of a substantial number of viral nonstructural and structural proteins were solved, 87 and targeted drug design was performed for some of those (reviewed in (17)). Unfortunately, 88 thus far none of these efforts resulted in antiviral drugs that were advanced beyond the 89 preclinical phase (18) . The 2003 SARS-CoV epidemic was controlled within a few months after 90 its onset and since then the virus has not re-emerged, although close relatives continue to 91 circulate in bat species (14) . Consequently, the interest in anti-coronavirus drug development 92 has been limited, until the emergence of MERS-CoV. Despite the modest size of this CoV 93 outbreak thus far, the lack of effective methods to prevent or treat coronavirus infections in 94 humans is a serious concern for the control of MERS-CoV or the next zoonotic coronavirus. 95 Antiviral research in the post-SARS era resulted in the identification of several 96 compounds that may target coronavirus replication directly or modulate the immune response 97 to coronavirus infection. For example, entry inhibitors targeting the coronavirus spike protein 98 were developed (reviewed in (19)). In addition, several of the replicative enzymes (including 99 both proteases and the helicase) were targeted with small-molecule inhibitors, some of which 100 can inhibit coronavirus infection in cell culture at low-micromolar concentrations ((20-26) and 101 reviewed in (26) and (27)). Broad spectrum antiviral agents, like the nucleoside analogue 102 6 ribavirin and interferon (IFN), were tested for their ability to inhibit SARS-CoV infection and 103 were -to a limited extent -used for the treatment of SARS patients during the outbreak 104 (reviewed by (28) and (29)). In the case of ribavirin, mixed results were reported from studies in 105 different cell lines, animal models, and patients. Also the merits of treating SARS patients with 106 immunomodulatory corticosteroids have remained a matter of debate (reviewed in (28-30) Frankfurt-1; (48)) were done as described before (34 Table   223 1). For CQ, an EC 50 value of 4.1 µM was observed ( Fig. 2A) , which is in line with earlier reports To investigate this, both compounds were added to cells 1 h before (t=-1) or after (t=+1) 241 infection (MOI of 1). Viral titers were determined at 24 h p.i. by plaque assay (Fig. 4) . Virus 242 production was not affected by CQ treatment when the compound was added at 1 h p.i. in vitro replication of MERS-CoV at low-micromolar concentrations ( Fig. 1 and Table 1 ). While 277 for some of these molecules the SI was limited (<10), for each of them we established at least 278 one concentration at which MERS-CoV replication was inhibited by more than 80% without a 279 detectable reduction of cell viability. The same four drugs were also found to inhibit, with 280 comparable potency, the in vitro replication of two other coronaviruses, i.e. HCoV-229E and 281 SARS-CoV (Fig. 2 and 3 and Table 1 ).
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CQ inhibited MERS-CoV replication with an EC 50 value of 3.0 µM (Fig. 1A) and blocked 283 infection at an early step (Fig. 5A ). CQ has a tendency to accumulate in lysosomes where it 284 sequesters protons and increases the pH. In addition, it interacts with many different proteins 285 and cellular processes, resulting in the modulation of autophagy and the immune response (for 286 a review see (59)). CQ has also been reported to inhibit the replication of multiple flaviviruses, 287 influenza viruses, HIV (reviewed in (60) (73), which is somewhat below the observed EC 50 values observed here (which range 314 between 2 and 9 µM). 315 The replication of MERS-CoV in vitro was also inhibited by LPM, an anti-diarrheal opioid-316 receptor agonist that reduces intestinal motility (reviewed in (74)). LPM also inhibits the 317 replication of two other coronaviruses at low-micromolar concentrations (4 to 6 µM). Upon oral 318 or intravenous administration, the molecule rapidly concentrates in the small intestine. Less 319 than 1% of orally taken LPM is absorbed from the gut lumen and its tendency to concentrate at 320 16 the site of action is the probable basis for its anti-diarrheal effect (75). This same property 321 would very much limit systemic use for the treatment of respiratory coronavirus infections, 322 although administration in the form of an aerosol might be explored. In the veterinary field, it 323 would be interesting to test whether the compound has the potential to inhibit enteric 324 coronaviruses such as the porcine transmissible gastroenteritis coronavirus. with some success in non-randomized clinical trials (for reviews, see (78, 79) particular the ~30% mortality rate within this group remains a grave concern. In this context, Chlorpromazine 4.9 (± 1.2) 21.3 (± 1.0) 4.3 8.8 (± 1.0) 24.3 (± 1.1) 2.8 2.5 (± 1.0) 23.5 (± 1.0) 9.4
Loperamide 4.8 (± 1.5) 15.5 (± 1.0) 3.2 5.9 (± 1.1) 53.8 (± 1.7) 9.1 4.0 (± 1.1) 25.9 (± 1.0) 6.0 Lopinavir 8.0 (± 1.5) 24.4 (± 1.0) 3.1 17.1 (± 1.0) >32 >2 6.6 (± 1.1) 37.6 (± 1.3) 5.7 a EC50 and CC50 values are means (± SD) from a representative experiment (n=4) that was repeated at least twice. Antiviral activity was determined in Huh7 cells (for MERS-CoV and HCoV-229E-GFP ) or VeroE6 cells (for SARS-CoV). See text for more details.
